• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    7/28/23 1:31:12 PM ET
    $BJDX
    $FEMY
    $FIXX
    $GMVD
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BJDX alert in real time by email

    Gainers

    • Reata Pharmaceuticals (NASDAQ:RETA) shares moved upwards by 52.1% to $165.09 during Friday's regular session. As of 13:30 EST, Reata Pharmaceuticals's stock is trading at a volume of 9.0 million, which is 1155.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.1 billion.
    • Homology Medicines (NASDAQ:FIXX) shares rose 37.22% to $1.29. As of 13:30 EST, this security is trading at a volume of 8.3 million shares, making up 5754.6% of its average full-day volume over the last 100 days. The company's market cap stands at $74.5 million.
    • Bluejay Diagnostics (NASDAQ:BJDX) stock increased by 32.52% to $7.09. As of 13:30 EST, Bluejay Diagnostics's stock is trading at a volume of 8.3 million, which is 3401.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.2 million.
    • Gracell Biotechnologies (NASDAQ:GRCL) shares increased by 26.16% to $4.05. Gracell Biotechnologies's stock is trading at a volume of 214.4K shares as of 13:30 EST. This is 64.1% of its average full-day volume over the last 100 days. The company's market cap stands at $274.2 million.
    • Pulse Biosciences (NASDAQ:PLSE) shares increased by 21.79% to $8.46. As of 13:30 EST, this security is trading at a volume of 208.5K shares, making up 144.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $403.0 million.
    • Larimar Therapeutics (NASDAQ:LRMR) shares rose 21.54% to $3.78. Trading volume for this security as of 13:30 EST is 1.5 million, which is 505.8% of its average full-day volume over the last 100 days. The company's market cap stands at $163.5 million.

    Losers

    • Tonix Pharmaceuticals (NASDAQ:TNXP) shares decreased by 41.0% to $1.05 during Friday's regular session. Trading volume for Tonix Pharmaceuticals's stock is 3.5 million as of 13:30 EST. This is 1265.4% of its average full-day volume over the last 100 days. The company's market cap stands at $10.8 million.
    • Mallinckrodt (AMEX:MNK) stock fell 21.6% to $1.27. Trading volume for this security as of 13:30 EST is 4.1 million, which is 108.1% of its average full-day volume over the last 100 days. The company's market cap stands at $16.7 million.
    • Intelligent Bio Solutions (NASDAQ:INBS) shares fell 19.44% to $1.91. Intelligent Bio Solutions's stock is trading at a volume of 137.6K shares as of 13:30 EST. This is 113.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.4 million.
    • G Medical Innovations (NASDAQ:GMVD) stock declined by 19.07% to $0.28. The current volume of 675.3K shares is 230.7% of G Medical Innovations's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $2.0 million.
    • Femasys (NASDAQ:FEMY) stock declined by 19.04% to $0.68. As of 13:30 EST, Femasys's stock is trading at a volume of 6.5 million, which is 195.2% of its average full-day volume over the last 100 days. The company's market cap stands at $10.2 million.
    • Marker Therapeutics (NASDAQ:MRKR) shares fell 17.2% to $6.89. The current volume of 331.8K shares is 37.9% of Marker Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $60.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BJDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BJDX
    $FEMY
    $FIXX
    $GMVD

    CompanyDatePrice TargetRatingAnalyst
    Pulse Biosciences Inc
    $PLSE
    1/30/2026$25.00Outperform
    Mizuho
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Pulse Biosciences Inc
    $PLSE
    7/7/2025$22.00Outperform
    Oppenheimer
    Marker Therapeutics Inc.
    $MRKR
    3/5/2025$8.00Buy
    Canaccord Genuity
    Larimar Therapeutics Inc.
    $LRMR
    1/29/2025$18.00Buy
    Truist
    Larimar Therapeutics Inc.
    $LRMR
    10/16/2024$26.00Outperform
    Oppenheimer
    Larimar Therapeutics Inc.
    $LRMR
    10/3/2024$22.00Outperform
    Wedbush
    Larimar Therapeutics Inc.
    $LRMR
    10/2/2024$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $BJDX
    $FEMY
    $FIXX
    $GMVD
    SEC Filings

    View All

    SEC Form 10-K filed by Bluejay Diagnostics Inc.

    10-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/6/26 4:02:15 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/6/26 9:21:49 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    3/3/26 4:34:48 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $BJDX
    $FEMY
    $FIXX
    $GMVD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SKYCLARYS issued to REATA PHARMACEUTICALS INC

    Submission status for REATA PHARMACEUTICALS INC's drug SKYCLARYS (ORIG-1) with active ingredient OMAVELOXOLONE has changed to 'Approval' on 02/28/2023. Application Category: NDA, Application Number: 216718, Application Classification: Type 1 - New Molecular Entity

    2/28/23 5:14:09 PM ET
    $RETA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BJDX
    $FEMY
    $FIXX
    $GMVD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

    ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent progress and its planned strategic trajectory through 2026. Operational and Clinical ProgressBluejay continues to advance its Symphony™ platform, including the Company's lead product candidate for the rapid measurement of Interleukin-6 (IL-6) to support sepsis risk assessment and critical-care decision making. The Company confirmed that its SYMON™ II clinical study is progressing as planned, with on

    3/6/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

    Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years The sublingual TONMYA tablet containing a basifying agent achieved the design objectives of rapid transmucosal absorption and bypassing first-pass liver metabolism TONMYA was designed to decrease production of the active metabolite norcyclobenzaprine, which is believed to improve the durability of analgesic response in fibromyalgia relative to the transient (~1 month) effects of oral, swallowed cyclobenzaprine BERKELEY HEIGHTS, N.J., March 05, 2026 (GLOBE NEWSWIRE

    3/5/26 4:15:00 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Pulse Biosciences' Management is scheduled to present on Wednesday, March 18, 2026, at 10:40 am ET. A live and recorded webcast of the fireside chat will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health inn

    3/5/26 7:00:00 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $BJDX
    $FEMY
    $FIXX
    $GMVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Pulse Biosciences with a new price target

    Mizuho initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $25.00

    1/30/26 6:44:12 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Laidlaw initiated coverage on Femasys with a new price target

    Laidlaw initiated coverage of Femasys with a rating of Buy and set a new price target of $6.50

    11/20/25 8:06:38 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on Pulse Biosciences with a new price target

    Oppenheimer initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $22.00

    7/7/25 8:02:36 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $BJDX
    $FEMY
    $FIXX
    $GMVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    * Director by Deputization Flynn James E bought $25,000,000 worth of shares (5,000,000 units at $5.00) (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 7:46:04 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hamilton Thomas Edward bought $500,000 worth of shares (100,000 units at $5.00), increasing direct ownership by 18% to 664,798 units (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 4:30:41 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thomas Frank E bought $25,000 worth of shares (5,000 units at $5.00), increasing direct ownership by 250% to 7,000 units (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 4:30:36 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BJDX
    $FEMY
    $FIXX
    $GMVD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    * Director by Deputization Flynn James E bought $25,000,000 worth of shares (5,000,000 units at $5.00) (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 7:46:04 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hamilton Thomas Edward bought $500,000 worth of shares (100,000 units at $5.00), increasing direct ownership by 18% to 664,798 units (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 4:30:41 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thomas Frank E bought $25,000 worth of shares (5,000 units at $5.00), increasing direct ownership by 250% to 7,000 units (SEC Form 4)

    4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

    3/2/26 4:30:36 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BJDX
    $FEMY
    $FIXX
    $GMVD
    Leadership Updates

    Live Leadership Updates

    View All

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

    CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated commercial-stage biotechnology company today announced the appointment of Irina Ishak as General Counsel, effective December 8, 2025. Ms. Ishak will lead Tonix's legal, corporate governance, and compliance functions. "Irina is a highly accomplished corporate and commercial attorney whose experience spans public and private life sciences companies, as well as advising life sciences investors," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. "Her deep background in complex transactions, public company matters, and governa

    12/9/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

    Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents of $190.1 million reported as of September 30, 2025; current cash runway expected to fund operations into the first quarter of 2027 CHATHAM, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial biotechnology company today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent operational highlights. "Following U.S. Food a

    11/10/25 4:15:00 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BJDX
    $FEMY
    $FIXX
    $GMVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

    SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

    11/14/24 5:05:19 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BJDX
    $FEMY
    $FIXX
    $GMVD
    Financials

    Live finance-specific insights

    View All

    Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success at one year, of evaluable patients, following treatments with the nPulse Cardiac Catheter System in the first-in-human feasibility study which was presented as late-breaking data at the 31st Annual AF Symposium Meeting. Receiv

    2/19/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 7647402. A live and recorded webcast of the event will be available on the Pulse Bioscie

    2/4/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care